Beneficial effects of erythropoietin in preclinical models of shock and organ failure.
Erythropoietin protects many organs against the tissue injury and dysfunction caused by ischaemia/reperfusion and excessive inflammation. This editorial comment discusses the effects of erythropoietin in preclinical models of septic shock, endotoxemia, hemorrhagic shock, spinal cord trauma and zymosan-induced multiple organ failure.
Thiemermann
Christoph
C
The William Harvey Research Institute, Queen Mary-University of London, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK. c.thiemermann@qmul.ac.uk
D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D019446:Endotoxemia / Q000188:drug therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D051379:Mice; D009102:Multiple Organ Failure / Q000188:drug therapy*; D012769:Shock / Q000188:drug therapy*; D012771:Shock, Hemorrhagic / Q000188:drug therapy; D012772:Shock, Septic / Q000188:drug therapy; D013119:Spinal Cord Injuries / Q000188:drug therapy; D016896:Treatment Outcome; D015054:Zymosan
D004921:Erythropoietin; D015054:Zymosan